Publication: The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
Loading...
Files
Date
2023-08-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: CDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear. Methods: This multicenter retrospective study included 204 HR+ breast cancer patients treated with a combination of CDK4/6 inhibitor and endocrine therapy. HER2-zero disease was detected in 138 (68%) and HER2-low disease in 66 (32%) patients. Treatment-related characteristics and clinical outcomes were analyzed, with a median follow-up of 22 months. Results: The objective response rate (ORR) was 72.7% in the HER2 low group and 66.6% in the HER2 zero group (p = 0.54). Median PFS was not significantly different between the HER2-low and HER2 zero groups (19 months vs.18 months, p = 0.89), although there was a trend toward longer PFS in the HER2-low group for first-line treatment (24 months progression-free survival rate 63% vs 49%). In recurrent disease, the median PFS was 25 months in the HER2-low group and 12 months in the HER2-zero group (p = 0.08), while in de novo metastatic disease, the median PFS was 18 months in the HER2-low group and 27 months in the HER2-zero group (p = 0.16). The order of CDK4/6 inhibitor use and the presence of visceral metastasis were identified as independent variables affecting PFS. Conclusion: Low HER2 expression did not significantly impact treatment response or PFS in HR+ breast cancer patients treated with a CDK4/6 inhibitor and endocrine therapy. Because of the conflicting results in the literature, further prospective studies are needed to evaluate the clinical significance of HER2 expression in HR+ breast cancer.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Cerrahi Tıp Bilimleri, Yaşam Bilimleri, Moleküler Biyoloji ve Genetik, Sitogenetik, Sağlık Bilimleri, Temel Bilimler, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Surgery Medicine Sciences, Life Sciences, Molecular Biology and Genetics, Cytogenetic, Health Sciences, Natural Sciences, Klinik Tıp (MED), Yaşam Bilimleri (LIFE), Klinik Tıp, CERRAHİ, ONKOLOJİ, BİYOKİMYA VE MOLEKÜLER BİYOLOJİ, Clinical Medicine (MED), Life Sciences (LIFE), CLINICAL MEDICINE, MOLECULAR BIOLOGY & GENETICS, SURGERY, ONCOLOGY, BIOCHEMISTRY & MOLECULAR BIOLOGY, Cerrahi, Kanser Araştırmaları, Surgery, Cancer Research, breast cancer, HER2-Low, hormone positive, palbociclib, ribociclib
Citation
ÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., UZUN M., KESKİNKILIÇ M., Tanrikulu Simsek E., Sari M., et al., "The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study", Breast, cilt.70, ss.56-62, 2023